Gliclazide and Bentyl drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gliclazide (gliclazide) and Bentyl (dicyclomine hydrochloride). Common drug interactions include rheumatoid arthritis among females and faecaloma among males.

The phase IV clinical study analyzes what interactions people have when they take Gliclazide and Bentyl. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.

What is Bentyl?

Bentyl has active ingredients of dicyclomine hydrochloride. It is often used in irritable bowel syndrome. eHealthMe is studying from 10,754 Bentyl users. Check the latest studies of Bentyl.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 02, 2026

17 people who take Gliclazide and Bentyl together, and have interactions are studied.

Gliclazide and Bentyl drug interactions.

What are the common drug interactions of Gliclazide and Bentyl, by gender? *:

female:

  1. Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)
  2. Arthralgia (joint pain)
  3. Asthenia (weakness)
  4. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  5. Cancer pain
  6. Cardiomyopathy (weakening of the heart muscle)
  7. Decreased appetite
  8. Depression
  9. Facet joint syndrome (problem with movement of the facet joints of the spine)
  10. Hepatic steatosis (fatty liver disease)

male:

  1. Faecaloma (hard mass of fecal matter)
  2. Headache (pain in head)

What are the common drug interactions of Gliclazide and Bentyl, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Dyspnoea (difficult or laboured respiration)
  2. Epistaxis (bleed from the nose)
  3. Pruritus (severe itching of the skin)

40-49:

  1. Abdominal pain upper
  2. Anxiety
  3. Arthropathy
  4. Atrophic vulvovaginitis (inflammation of the vulva)
  5. Carotid artery disease
  6. Carotid artery occlusion (artery blockage)
  7. Chronic kidney disease
  8. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  9. Cough
  10. Deafness

50-59:

  1. Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)

60+:

  1. Arthralgia (joint pain)
  2. Asthenia (weakness)
  3. Hypokalaemia (low potassium)
  4. Intervertebral disc degeneration (spinal disc degeneration)
  5. Microcytic anaemia (a generic term for any type of anaemia characterized by small red blood cells)
  6. Muscle strain (an injury to a muscle in which the muscle fibres tear)
  7. Oedema (fluid collection in tissue)
  8. Pain
  9. Pyelonephritis acute (sudden inflammation of kidney caused by bacteria)
  10. Rash

What are the existing conditions these people have? *

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 8 people, 47.06%
  2. Pain: 6 people, 35.29%
  3. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 6 people, 35.29%
  4. High Blood Pressure: 4 people, 23.53%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 23.53%
  6. Asthma: 3 people, 17.65%
  7. Herpes Zoster: 2 people, 11.76%
  8. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 11.76%
  9. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 11.76%
  10. Allergic Rhinitis: 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and Bentyl?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Gliclazide and Bentyl:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gliclazide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Bentyl:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gliclazide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Bentyl and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gliclazide and dicyclomine hydrochloride (the active ingredients of Gliclazide and Bentyl, respectively), and Gliclazide and Bentyl (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: